Predicta Biosciences utilizes a blood-based platform that integrates multiomic diagnostics, including genomics and transcriptomics, to enhance precision medicine. This innovative approach allows for noninvasive blood draws, which replace traditional invasive procedures like bone marrow biopsies. By leveraging big data analytics and artificial intelligence, Predicta analyzes comprehensive patient data to provide insights into disease biology, enabling early detection, accurate diagnosis, and personalized treatment guidance. The platform's ability to continuously monitor patients through routine blood tests facilitates timely interventions, ultimately improving patient outcomes in cancer care.

The company is focused on building a robust patient database that enhances its diagnostic and therapeutic discovery capabilities. By employing advanced computational and statistical methods, Predicta aims to identify novel therapeutic targets and optimize treatment strategies tailored to individual patients. This commitment to harnessing patient data not only drives the development of more effective therapies but also contributes to a deeper understanding of disease mechanisms, particularly in blood cancers. The leadership team, composed of experts in genomics and oncology, underscores Predicta's dedication to advancing cancer treatment through innovative technologies.

United States

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

Predicta Biosciences

Company Details